Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):289–296. doi: 10.1097/QAI.0000000000000968

Table 3.

Rilpivirine Pharmacokinetic Parameters Geometric Mean (90% CI) Ratios

Parameters Second Trimester/
Third Trimester,
n = 15		 Second Trimester/
Postpartum,
n = 15		 Third Trimester/
Postpartum,
n = 28
AUC24 (ng*hr/mL) 1.09 (0.96 – 1.23) 0.77 (0.61 – 0.96) 0.80 (0.62 – 1.03)
C0 (ng/mL) 1.30 (1.06 – 1.60) 0.91 (0.61 – 1.38) 0.94 (0.59 – 1.50)
Cmax (ng/mL) 1.13 (0.96 – 1.34) 0.84 (0.69 – 1.02) 0.83 (0.68 – 1.01)
C24 (ng/mL) 1.09 (0.95 – 1.26) 0.70 (0.55 – 0.90) 0.84 (0.57 – 1.23)
Cmin (ng/mL) 1.22(1.02 – 1.45) 0.88 (0.63 – 1.21) 1.11 (0.70 – 1.74)
Vd/F (L) 0.36(0.22 – 0.58) 1.50 (0.58 – 3.93) 1.42 (0.68 – 2.97)
CL/F (L/hr) 0.92 (0.81 – 1.05) 1.33 (1.04 – 1.70) 1.26 (0.97 – 1.64)

Abbreviations: AUC24, area under the concentration-time curve through 24 hours post-dose; C0, pre-dose concentration; Cmax, maximum concentration; C24, 24 hour post-dose concentration; Cmin, minimum observed concentration at any time post-dose; Vd/F, apparent volume of distribution; CL/F, oral clearance.